2009-11-10 21:40:05 -

IntraOp Medical Corporation (OTCBB: IOPD) today announced that it has filed an amendment to its articles of incorporation to effect a reverse stock split, whereby each 50 shares of common stock was combined into one share of common stock. The outstanding share count after giving effect to the reverse split is now approximately 7.8 million shares, reduced from approximately 392.8

million shares. In addition, the company has reduced the number of authorized shares of common stock from 500 million to 100 million and authorized a class of up to 20 million shares of preferred stock for future fund raising rounds.

By effecting the reverse split and thereby reducing the company’s outstanding share count, IntraOp hopes to make the company’s stock more appealing to larger, institutional investors in its capital raising efforts.

“We have made significant progress this year towards our cost reduction and market development goals,” said John Powers, CEO of IntraOp Medical.

“We are now in the phase where we need to raise a new round of capital to fully execute on our dermatology and IORT market strategies. This stock split enhances our ability to attract larger institutional investors and properly prepare for the future.”


IntraOp’s common stock began trading on a post-split basis on November 10, 2009. IntraOp’s ticker symbol has changed to IOPD.


About IntraOp

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intra-operative and office–based radiation therapy safely and effectively – for all cancer patients. The company’s flagship product, Mobetron, is the first fully portable, self-shielding intra-operative electron radiation therapy device designed for use in any operating room or office setting. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program. In addition, IntraOp’s DermaBeam technology is forging a new paradigm in the effective, efficient treatment of skin cancers in dermatology offices nationwide.

For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com :



Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.


HealthFlash MarketingJeanne-Marie Phillips, 888-655-3434 jphillips@healthflashmarketing.com : mailto:jphillips@healthflashmarketing.com